BioCryst Pharmaceuticals BCRX Common stock, capital shares reserved for future issuance
Common stock, capital shares reserved for future issuance at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CommonStockCapitalSharesReservedForFutureIssuance.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's common stock, capital shares reserved for future issuance.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's common stock, capital shares reserved for future issuance?
- BioCryst Pharmaceuticals (BCRX) reported common stock, capital shares reserved for future issuance of $64.83M in Q1 2026.
- How has BioCryst Pharmaceuticals's common stock, capital shares reserved for future issuance changed year-over-year?
- BioCryst Pharmaceuticals's common stock, capital shares reserved for future issuance increased by 5.4% year-over-year, from $61.49M to $64.83M.
- What is the long-term trend for BioCryst Pharmaceuticals's common stock, capital shares reserved for future issuance?
- Over 3 years (2022 to 2025), BioCryst Pharmaceuticals's common stock, capital shares reserved for future issuance has grown at a 0.6% compound annual growth rate (CAGR), from $67.24M to $68.5M.